EGFR and neoplasm: Concerning the central role of EGFR and PD-L1 in the pathogenesis and therapy of HNSCC, hypoxia-mediated modulation of receptor tyrosine kinase signaling or the immunologic status might represent another paradigm for therapy resistance mediated by tumor microenvironmental traits.